Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announced today that Seth Lederman, M.D., Chief Executive Officer ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien ...

TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tramadol, a potent synthetic opioid, has been widely used to treat moderate to severe pain, but a new study suggests that the medication’s potential risks outweigh its “limited” benefits for chronic ...

The strong opioid painkiller tramadol is not significantly effective at easing the chronic pain for which it's widely prescribed, finds a pooled data analysis of the available research, published in ...

A review of existing research has found that tramadol’s pain relief benefits are minimal and may be outweighed by serious side effects, challenging the drug’s reputation as a “safer” opioid option for ...

A new study suggests the painkiller tramadol is only of limited benefit for chronic pain Alamy/PA, The painkiller tramadol only has a slight effect on chronic pain and its side-effects may outweigh ...